Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

ABSTRACT:

Background

Change in breast density may predict outcome of women receiving adjuvant hormone therapy for breast cancer. We performed a prospective clinical trial to evaluate the impact of inherited variants in genes involved in oestrogen metabolism and signalling on change in mammographic percent density (MPD) with aromatase inhibitor (AI) therapy.

Methods

Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes. Subjects underwent unilateral craniocaudal mammography before and following 24 months of treatment.

Results

Of the 503 enrolled s

SUBMITTER: Henry NL 

PROVIDER: S-EPMC3817329 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature